Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death
- PMID: 20114048
- DOI: 10.1053/j.gastro.2010.01.042
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death
Abstract
Background & aims: The risk and the predictors of liver disease progression in carriers of inactive hepatitis B virus (HBV) are unclear.
Methods: Participants in the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study who were seronegative for hepatitis B e antigen; had serum levels of HBV DNA <10,000 copies/mL; and did not have cirrhosis, hepatocellular carcinoma, or increased serum levels of alanine aminotransferase were classified as carriers of inactive HBV (n = 1932). Study participants who were seronegative for HB surface antigen and antibodies against hepatitis C virus, yet had similar clinical liver features, were the controls (n = 18,137). Liver-related death and new cases of hepatocellular carcinoma were ascertained through computerized data linkage with National Cancer Registry and Death Certification profiles. The disease progression rates were estimated. The multivariate-adjusted hazard ratios for risk predictors were derived from Cox regression models.
Results: There were 20,069 participants, contributing a total of 262,122 person-years, with a mean follow-up of 13.1 years. Annual incidence rates of hepatocellular carcinoma and liver-related death were 0.06% and 0.04%, respectively, for inactive HBV carriers; rates were 0.02%, and 0.02% for controls, respectively. The multivariate-adjusted hazard ratios for carriers of inactive HBV, compared to controls, were 4.6 (95% confidence interval: 2.5-8.3) for hepatocellular carcinoma and 2.1 (95% confidence interval: 1.1-4.1) for liver-related death. Older age and alcohol drinking habits were independent predictors of risk for carriers of inactive HBV to develop hepatocellular carcinoma.
Conclusions: Carriers of inactive HBV have a substantial risk of hepatocellular carcinoma and liver-related death compared with individuals not infected with HBV.
Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.J Natl Cancer Inst. 2009 Jul 15;101(14):1019-27. doi: 10.1093/jnci/djp146. Epub 2009 Jun 17. J Natl Cancer Inst. 2009. PMID: 19535774
-
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.Gastroenterology. 2011 Oct;141(4):1240-8, 1248.e1-2. doi: 10.1053/j.gastro.2011.06.036. Epub 2011 Jun 22. Gastroenterology. 2011. PMID: 21703214
-
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.J Clin Oncol. 2010 May 10;28(14):2437-44. doi: 10.1200/JCO.2009.27.4456. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368541
-
Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.J Biomed Sci. 2008 Mar;15(2):137-45. doi: 10.1007/s11373-007-9225-8. Epub 2007 Dec 5. J Biomed Sci. 2008. PMID: 18058038 Review.
Cited by
-
Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi.Int J Mol Sci. 2020 Jan 31;21(3):949. doi: 10.3390/ijms21030949. Int J Mol Sci. 2020. PMID: 32023902 Free PMC article. Review.
-
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.JHEP Rep. 2019 Jun 28;1(3):170-178. doi: 10.1016/j.jhepr.2019.06.001. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039367 Free PMC article.
-
Diagnostic precision of Truenat® technique and co-relation of ALT levels with HBV-DNA viral load among HBsAg positive patients at a tertiary care hospital in Eastern Uttar Pradesh.Iran J Microbiol. 2024 Feb;16(1):132-138. doi: 10.18502/ijm.v16i1.14882. Iran J Microbiol. 2024. PMID: 38682056 Free PMC article.
-
Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.Emerg Microbes Infect. 2024 Dec;13(1):2339944. doi: 10.1080/22221751.2024.2339944. Epub 2024 Apr 16. Emerg Microbes Infect. 2024. PMID: 38584592 Free PMC article.
-
Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.Gastroenterol Hepatol (N Y). 2010 Sep;6(9 Suppl 16):1-16. Gastroenterol Hepatol (N Y). 2010. PMID: 22423222 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical